Updates in Cardiology and Beyond

Updates in Cardiology and Beyond A Page for Sharing Practice Changing Updates in Cardiology and Beyond

🔴 Trial (ACC, 2026)RCT evaluating in pts with HF with Rheumatic Heart Disease ( )Key results: 💊 4% RR ⤵️ of primary ...
01/04/2026

🔴 Trial (ACC, 2026)

RCT evaluating in pts with HF with Rheumatic Heart Disease ( )

Key results:

💊 4% RR ⤵️ of primary endpoint driven in those Rx with digoxin by ⤵️ worsening HF.

💊 Hospitalization for HF was very infrequent (mortality rate of 2.8 vs 4.9 per 100 pt-years).

💊 1st trial evidence for digoxin as a safe Rx for reducing HF worsening in RHD.

🔴 Trial (ACC, 2026)• Mineralocorticoid receptor antagonists are foundational in HF—but gaps remain.• This trial evalua...
01/04/2026

🔴 Trial (ACC, 2026)

• Mineralocorticoid receptor antagonists are foundational in HF—but gaps remain.

• This trial evaluated spironolactone in &

➡️ Key results:

♥️Unable to demonstrate a benefit of spironolactone in HFpEF or HFmEF compared with placebo
♥️50% discontinuation of Spiro due to side effects
♥️Underpowered trial

🔴 Trial (NEJM, 2026)Discontinuation of Beta-Blocker (BB) Therapy after MI (NEJM, 2026)Trial sites: 25 Centers in South...
31/03/2026

🔴 Trial (NEJM, 2026)

Discontinuation of Beta-Blocker (BB) Therapy after MI (NEJM, 2026)

Trial sites: 25 Centers in South Korea

Population:

• N = 2540 stable post-MI pts
• LVEF ≥40%
• No HF
• On BBs ≥1 year (n=2,540)

Study type:

• Open-label, randomized, noninferiority trial
• Median follow-up: 3.1 years

Intervention: Discontinue vs continue BB

Primary outcome: Composite of all-cause death, recurrent MI, or HF hospitalization

Results:

• Primary endpoint: 7.2 (discontinue) vs 9.0% (continue); HR 0.80 (95% CI 0.57–1.13)
• Serious adverse events: similar b/n groups

Conclusions:

• Among pts who received BB therapy beyond the 1st year after MI, discontinuation was noninferior to continuation with respect to a composite of death from any cause, recurrent MI, or hospitalization for HF

https://www.nejm.org/doi/full/10.1056/NEJMoa2601005?query=featured_home

🔴 vs after in atrial fibrillation ( ): 1-year outcomes in the study and inconcurrent practice (ESJ, 2026)• In ...
31/03/2026

🔴 vs after in atrial fibrillation ( ): 1-year outcomes in the study and inconcurrent practice (ESJ, 2026)

• In TIMING, adults with AF were randomised to initiation of DOAC either within 4 days orat 5–10 days after acute ischaemic stroke.

• At 1-year follow-up, early initiation of DOAC remained safe and effective with no increase in symptomatic intracerebral haemorrhage.

• The results support early DOAC initiation in pts with acute ischaemic stroke and AF.
https://academic.oup.com/esj/article/11/2/aakag010/8501222

🔴 and Lifetime Risk of Coronary Heart Disease ( ): Cohort Study (JAMA, 2026)• In this cohort study, premature menopaus...
31/03/2026

🔴 and Lifetime Risk of Coronary Heart Disease ( ): Cohort Study (JAMA, 2026)

• In this cohort study, premature menopause was associated with 40% higher lifetime risk of CHD in Black and White women.

• This suggests that premature onset of menopause is an important risk-enhancing factorfor lifetime risk and should be routinely assessed in clinical practice to consider intensification of preventive efforts.

https://jamanetwork.com/journals/jamacardiology/article-abstract/2846695

🔵 How to interpret during ? • D-dimer is physiologically ↑ • Standard cutoff can mislead!💡 Use algorithm with D-dim...
30/03/2026

🔵 How to interpret during ?

• D-dimer is physiologically ↑

• Standard cutoff can mislead!

💡 Use algorithm with D-dimer

✅ Safe PE exclusion

🎯 Less unnecessary radiation

📚 From Tips & Tricks in Cardiology

🔴 Oral and Outcomes in Persons With T2D: A 2ry Analysis of the Trial (JAMA, 2026)✅ In this secondary analysis of ...
26/03/2026

🔴 Oral and Outcomes in Persons With T2D: A 2ry Analysis of the Trial (JAMA, 2026)

✅ In this secondary analysis of the SOUL trial, among individuals with T2D, atherosclerotic CV disease, and/or CKD, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a hx of HF, without increasing the risk of serious adverse events.

✅ These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844096

🔴 A Post Hoc Secondary Analysis of the Trial (JAMA, 2026)Oral Semaglutide and Change in CV Risk Factors in High-Risk T...
26/03/2026

🔴 A Post Hoc Secondary Analysis of the Trial (JAMA, 2026)

Oral Semaglutide and Change in CV Risk Factors in High-Risk Type 2 Diabetes

✅ In this post hoc secondary analysis of the SOUL trial, oral semaglutide was associated with early and sustained improvements vsplacebo in multiple ASCVD risk factors in high-risk participants with T2D and ASCVDand/or CKD, incremental to standard of care.

https://jamanetwork.com/journals/jamacardiology/fullarticle/2847041

Address

Addis Ababa

Website

Alerts

Be the first to know and let us send you an email when Updates in Cardiology and Beyond posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category